Nordic guidelines 2014 for diagnosis and treatment of gastroenteropancreatic neuroendocrine neoplasms

References

• Yao JC, Hassan M, Phan A, Dagohoy C, Leary C, Mares JE, et al. One hundred years after ‘carcinoid’: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 2008;26:3063–72.
   PubMed Web of Science ®Google Scholar
• Lepage C, Bouvier AM, Faivre J. Endocrine tumours: Epidemiology of malignant digestive neuroendocrine tumours. Eur J Endocrinol 2013;168:R77–83.
   PubMed Web of Science ®Google Scholar
• Lawrence B, Gustafsson BI, Chan A, Svejda B, Kidd M, Modlin IM. The epidemiology of gastroenteropancreatic neuroendocrine tumors. Endocrinol Metab Clin North Am 2011;40:1–18, vii.
   PubMed Web of Science ®Google Scholar
• Korse CM, Taal BG, van Velthuysen ML, Visser O. Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: Experience of two decades of cancer registry. Eur J Cancer Care 2013; 49:1975–83.
   Web of Science ®Google Scholar
• van der Zwan JM, Trama A, Otter R, Larranaga N, Tavilla A, Marcos-Gragera R, et al. Rare neuroendocrine tumours: Results of the surveillance of rare cancers in Europe project. Eur J Cancer Care 2013;49:2565–78.
   Web of Science ®Google Scholar
• Mocellin S, Nitti D. Gastrointestinal carcinoid: Epidemiological and survival evidence from a large population-based study (n = 25 531). Ann Oncol 2013;24:3040–4.
   PubMed Web of Science ®Google Scholar
• Kanakis G, Kaltsas G. Biochemical markers for gastroenteropancreatic neuroendocrine tumours (GEP-NETs). Best Pract Res Clin Gastroenterol 2012;26:791–802.
   PubMed Web of Science ®Google Scholar
• Janson ET, Holmberg L, Stridsberg M, Eriksson B, Theodorsson E, Wilander E, et al. Carcinoid tumors: Analysis of prognostic factors and survival in 301 patients from a referral center. Ann Oncol 1997;8:685–90.
   PubMed Web of Science ®Google Scholar
• Welin S, Stridsberg M, Cunningham J, Granberg D, Skogseid B, Oberg K, et al. Elevated plasma chromogranin A is the first indication of recurrence in radically operated midgut carcinoid tumors. Neuroendocrinology 2009;89:302–7.
   PubMed Web of Science ®Google Scholar
• Jensen KH, Hilsted L, Jensen C, Mynster T, Rehfeld JF, Knigge U. Chromogranin A is a sensitive marker of progression or regression in ileo-cecal neuroendocrine tumors. Scand J Gastroenterol 2013;48:70–7.
   PubMed Web of Science ®Google Scholar
• Tropea F, Baldari S, Restifo G, Fiorillo MT, Surace P, Herberg A. Evaluation of chromogranin A expression in patients with non-neuroendocrine tumours. Clin Drug Investig 2006;26:715–22.
   PubMed Web of Science ®Google Scholar
• Stridsberg M, Eriksson B, Oberg K, Janson ET. A comparison between three commercial kits for chromogranin A measurements. J Endocrinol 2003;177:337–41.
   PubMed Web of Science ®Google Scholar
• Gedde-Dahl M, Thiis-Evensen E, Tjolsen AM, Mordal KS, Vatn M, Bergestuen DS. Comparison of 24-h and overnight samples of urinary 5-hydroxyindoleacetic acid in patients with intestinal neuroendocrine tumors. Endocr Connect 2013;2:50–4.
   PubMedGoogle Scholar
• Tohmola N, Itkonen O, Sane T, Markkanen H, Joenvaara S, Renkonen R, et al. Analytical and preanalytical validation of a new mass spectrometric serum 5-hydroxyindoleacetic acid assay as neuroendocrine tumor marker. Clin Chim Acta 2014;428:38–43.
   PubMed Web of Science ®Google Scholar
• Yao JC, Pavel M, Phan AT, Kulke MH, Hoosen S, St Peter J, et al. Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus. J Clin Endocrinol Metab 2011;96:3741–9.
   PubMed Web of Science ®Google Scholar
• Elias D, Lefevre JH, Duvillard P, Goere D, Dromain C, Dumont F, et al. Hepatic metastases from neuroendocrine tumors with a ‘thin slice’ pathological examination: They are many more than you think. Ann Surg 2010;251:307–10.
   PubMed Web of Science ®Google Scholar
• Sundin A. Radiological and nuclear medicine imaging of gastroenteropancreatic neuroendocrine tumours. Best Pract Res Clin Gastroenterol 2012;26:803–18.
   PubMed Web of Science ®Google Scholar
• Brenner R, Metens T, Bali M, Demetter P, Matos C. Pancreatic neuroendocrine tumor: Added value of fusion of T2-weighted imaging and high b-value diffusion-weighted imaging for tumor detection. Eur Radiol 2012;81:e746–9.
   Web of Science ®Google Scholar
• Schraml C, Schwenzer NF, Sperling O, Aschoff P, Lichy MP, Muller M, et al. Staging of neuroendocrine tumours: Comparison of [(6)(8)Ga]DOTATOC multiphase PET/CT and whole-body MRI. Cancer Imaging 2013;13:63–72.
   PubMed Web of Science ®Google Scholar
• Massironi S, Conte D, Sciola V, Pirola L, Paggi S, Fraquelli M, et al. Contrast-enhanced ultrasonography in evaluating hepatic metastases from neuroendocrine tumours. Dig Liver Dis 2010;42:635–41.
   PubMedGoogle Scholar
• Atiq M, Bhutani MS, Bektas M, Lee JE, Gong Y, Tamm EP, et al. EUS-FNA for pancreatic neuroendocrine tumors: A tertiary cancer center experience. Dig Dis Sci 2012;57: 791–800.
   PubMed Web of Science ®Google Scholar
• Sundin A, Rockall A. Therapeutic monitoring of gastroenteropancreatic neuroendocrine tumors: The challenges ahead. Neuroendocrinology 2012;96:261–71.
   PubMed Web of Science ®Google Scholar
• Velikyan I, Sundin A, Eriksson B, Lundqvist H, Sorensen J, Bergstrom M, et al. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours – impact of peptide mass. Nucl Med Biol 2010;37:265–75.
   PubMed Web of Science ®Google Scholar
• Pfeifer A, Knigge U, Mortensen J, Oturai P, Berthelsen AK, Loft A, et al. Clinical PET of neuroendocrine tumors using 64Cu-DOTATATE: First-in-humans study. J Nucl Med 2012;53:1207–15.
   PubMed Web of Science ®Google Scholar
• Sandstrom M, Velikyan I, Garske-Roman U, Sorensen J, Eriksson B, Granberg D, et al. Comparative biodistribution and radiation dosimetry of 68Ga-DOTATOC and 68Ga-DOTATATE in patients with neuroendocrine tumors. J Nucl Med 2013;54:1755–9.
   PubMed Web of Science ®Google Scholar
• Garin E, Le Jeune F, Devillers A, Cuggia M, de Lajarte-Thirouard AS, Bouriel C, et al. Predictive value of 18F-FDG PET and somatostatin receptor scintigraphy in patients with metastatic endocrine tumors. J Nucl Med 2009;50:858–64.
   PubMed Web of Science ®Google Scholar
• Binderup T, Knigge U, Loft A, Federspiel B, Kjaer A. 18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors. Clin Cancer Res 2010;16:978–85.
   PubMed Web of Science ®Google Scholar
• Norlen O, Stalberg P, Oberg K, Eriksson J, Hedberg J, Hessman O, et al. Long-term results of surgery for small intestinal neuroendocrine tumors at a tertiary referral center. World J Surg 2012;36:1419–31.
   PubMed Web of Science ®Google Scholar
• Capurso G, Bettini R, Rinzivillo M, Boninsegna L, Delle Fave G, Falconi M. Role of resection of the primary pancreatic neuroendocrine tumour only in patients with unresectable metastatic liver disease: A systematic review. Neuroendocrinology 2011;93:223–9.
   PubMed Web of Science ®Google Scholar
• Norlen O, Hessman O, Stalberg P, Akerstrom G, Hellman P. Prophylactic cholecystectomy in midgut carcinoid patients. World J Surg 2010;34:1361–7.
   PubMed Web of Science ®Google Scholar
• Moertel CG, Hanley JA, Johnson LA. Streptozocin alone compared with streptozocin plus fluorouracil in the treatment of advanced islet-cell carcinoma. N Engl J Med 1980;303:1189–94.
   PubMed Web of Science ®Google Scholar
• Dahan L, Bonnetain F, Rougier P, Raoul JL, Gamelin E, Etienne PL, et al. Phase III trial of chemotherapy using 5-fluorouracil and streptozotocin compared with interferon alpha for advanced carcinoid tumors: FNCLCC-FFCD 9710. Endocr Relat Cancer 2009;16:1351–61.
   PubMed Web of Science ®Google Scholar
• Strosberg JR, Fine RL, Choi J, Nasir A, Coppola D, Chen DT, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011;117:268–75.
   PubMed Web of Science ®Google Scholar
• Kulke MH, Hornick JL, Frauenhoffer C, Hooshmand S, Ryan DP, Enzinger PC, et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 2009;15:338–45.
   PubMed Web of Science ®Google Scholar
• Modlin IM, Pavel M, Kidd M, Gustafsson BI. Review article: Somatostatin analogues in the treatment of gastroenteropancreatic neuroendocrine (carcinoid) tumours. Aliment Pharmacol Ther 2010;31:169–88.
   PubMed Web of Science ®Google Scholar
• Rinke A, Muller HH, Schade-Brittinger C, Klose KJ, Barth P, Wied M, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID Study Group. J Clin Oncol 2009;27:4656–63.
   PubMed Web of Science ®Google Scholar
• Caplin M, Pavel M, Cwikla JB, Phan AT, Raderer M, Sedlackova E et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med 2014;371: 224–33.
   PubMed Web of Science ®Google Scholar
• Kvols LK, Oberg KE, O’Dorisio TM, Mohideen P, de Herder WW, Arnold R, et al. Pasireotide (SOM230) shows efficacy and tolerability in the treatment of patients with advanced neuroendocrine tumors refractory or resistant to octreotide LAR: Results from a phase II study. Endocr Relat Cancer 2012;19:657–66.
   PubMed Web of Science ®Google Scholar
• Oberg K. Biotherapies for GEP-NETs. Best Pract Res Clin Gastroenterol 2012;26:833–41.
   PubMed Web of Science ®Google Scholar
• Kwekkeboom DJ, de Herder WW, Kam BL, van Eijck CH, van Essen M, Kooij PP, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: Toxicity, efficacy, and survival. J Clin Oncol 2008; 26:2124–30.
   PubMed Web of Science ®Google Scholar
• Imhof A, Brunner P, Marincek N, Briel M, Schindler C, Rasch H, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011;29:2416–23.
   PubMed Web of Science ®Google Scholar
• Villard L, Romer A, Marincek N, Brunner P, Koller MT, Schindler C, et al. Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol 2012;30:1100–6.
   PubMed Web of Science ®Google Scholar
• van Essen M, Krenning EP, Kam BL, de Herder WW, Feelders RA, Kwekkeboom DJ. Salvage therapy with (177)Lu-octreotate in patients with bronchial and gastroenteropancreatic neuroendocrine tumors. J Nucl Med 2010;51:383–90.
   PubMed Web of Science ®Google Scholar
• Ezziddin S, Opitz M, Attassi M, Biermann K, Sabet A, Guhlke S, et al. Impact of the Ki-67 proliferation index on response to peptide receptor radionuclide therapy. Eur J Nucl Med Mol 2011;38:459–66.
   PubMed Web of Science ®Google Scholar
• Pavel ME, Hainsworth JD, Baudin E, Peeters M, Horsch D, Winkler RE, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): A randomised, placebo-controlled, phase 3 study. Lancet 2011;378:2005–12.
   PubMed Web of Science ®Google Scholar
• Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011;364:514–23.
   PubMed Web of Science ®Google Scholar
• Raymond E, Dahan L, Raoul JL, Bang YJ, Borbath I, Lombard-Bohas C, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011;364:501–13.
   PubMed Web of Science ®Google Scholar
• Jensen RT, Berna MJ, Bingham DB, Norton JA. Inherited pancreatic endocrine tumor syndromes: Advances in molecular pathogenesis, diagnosis, management, and controversies. Cancer 2008;113:1807–43.
   PubMed Web of Science ®Google Scholar
• Halfdanarson TR, Rabe KG, Rubin J, Petersen GM. Pancreatic neuroendocrine tumors (PNETs): Incidence, prognosis and recent trend toward improved survival. Ann Oncol 2008;19:1727–33.
   PubMed Web of Science ®Google Scholar
• Anderson MA, Carpenter S, Thompson NW, Nostrant TT, Elta GH, Scheiman JM. Endoscopic ultrasound is highly accurate and directs management in patients with neuroendocrine tumors of the pancreas. Am J Gastroenterol 2000;95:2271–7.
   PubMed Web of Science ®Google Scholar
• Birnbaum DJ, Gaujoux S, Cherif R, Dokmak S, Fuks D, Couvelard A, et al. Sporadic nonfunctioning pancreatic neuroendocrine tumors: Prognostic significance of incidental diagnosis. Surgery 2014;155:13–21.
   PubMed Web of Science ®Google Scholar
• Kulke MH, Bergsland EK, Yao JC. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med 2009;360:195–7.
   PubMed Web of Science ®Google Scholar
• Ekeblad S, Sundin A, Janson ET, Welin S, Granberg D, Kindmark H, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007;13:2986–91.
   PubMed Web of Science ®Google Scholar
• Cunningham JL, Diaz de Stahl T, Sjoblom T, Westin G, Dumanski JP, Janson ET. Common pathogenetic mechanism involving human chromosome 18 in familial and sporadic ileal carcinoid tumors. Genes Chromosomes Cancer 2011;50:82–94.
   PubMed Web of Science ®Google Scholar
• Capurso G, Rinzivillo M, Bettini R, Boninsegna L, Delle Fave G, Falconi M. Systematic review of resection of primary midgut carcinoid tumour in patients with unresectable liver metastases. Br J Surg 2012;99:1480–6.
   PubMed Web of Science ®Google Scholar
• Kolby L, Persson G, Franzen S, Ahren B. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 2003;90:687–93.
   PubMed Web of Science ®Google Scholar
• Arnold R, Rinke A, Klose KJ, Muller HH, Wied M, Zamzow K, et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: A randomized trial. Clin Gastroenterol Hepatol 2005;3: 761–71.
   PubMed Web of Science ®Google Scholar
• Faiss S, Pape UF, Bohmig M, Dorffel Y, Mansmann U, Golder W, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors – the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003;21:2689–96.
   PubMed Web of Science ®Google Scholar
• Grozinsky-Glasberg S, Alexandraki KI, Barak D, Doviner V, Reissman P, Kaltsas GA, et al. Current size criteria for the management of neuroendocrine tumors of the appendix: Are they valid? Clinical experience and review of the literature. Neuroendocrinology 2013;98:31–7.
   PubMed Web of Science ®Google Scholar
• McGory ML, Maggard MA, Kang H, O’Connell JB, Ko CY. Malignancies of the appendix: Beyond case series reports. Dis Colon Rectum 2005;48:2264–71.
   PubMed Web of Science ®Google Scholar
• Eriksson J, Stalberg P, Nilsson A, Krause J, Lundberg C, Skogseid B, et al. Surgery and radiofrequency ablation for treatment of liver metastases from midgut and foregut carcinoids and endocrine pancreatic tumors. World J Surgery 2008;32:930–8.
   PubMed Web of Science ®Google Scholar
• Knigge U, Hansen CP. Surgery for GEP-NETs. Best Pract Res Clin Gastroenterol 2012;26:819–31.
   PubMed Web of Science ®Google Scholar
• Maire F, Lombard-Bohas C, O’Toole D, Vullierme MP, Rebours V, Couvelard A, et al. Hepatic arterial embolization versus chemoembolization in the treatment of liver metastases from well-differentiated midgut endocrine tumors: A prospective randomized study. Neuroendocrinology 2012; 96:294–300.
   PubMed Web of Science ®Google Scholar
• Gupta S, Johnson MM, Murthy R, Ahrar K, Wallace MJ, Madoff DC, et al. Hepatic arterial embolization and chemoembolization for the treatment of patients with metastatic neuroendocrine tumors: Variables affecting response rates and survival. Cancer 2005;104:1590–602.
   PubMed Web of Science ®Google Scholar
• Kalinowski M, Dressler M, Konig A, El-Sheik M, Rinke A, Hoffken H, et al. Selective internal radiotherapy with Yttrium-90 microspheres for hepatic metastatic neuroendocrine tumors: A prospective single center study. Digestion 2009;79:137–42.
   PubMed Web of Science ®Google Scholar
• Paprottka PM, Hoffmann RT, Haug A, Sommer WH, Raessler F, Trumm CG, et al. Radioembolization of symptomatic, unresectable neuroendocrine hepatic metastases using yttrium-90 microspheres. J Vasc Interv Radiol 2012;35:334–42.
   Web of Science ®Google Scholar
• Le Treut YP, Gregoire E, Klempnauer J, Belghiti J, Jouve E, Lerut J, et al. Liver transplantation for neuroendocrine tumors in Europe – results and trends in patient selection: A 213-case European liver transplant registry study. Ann Surg 2013;257:807–15.
   PubMed Web of Science ®Google Scholar
• Sorbye H, Welin S, Langer SW, Vestermark LW, Holt N, Osterlund P, et al. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study. Ann Oncol 2013;24: 152–60.
   PubMed Web of Science ®Google Scholar
• Binderup T, Knigge U, Loft A, Mortensen J, Pfeifer A, Federspiel B, et al. Functional imaging of neuroendocrine tumors: A head-to-head comparison of somatostatin receptor scintigraphy, 123I-MIBG scintigraphy, and 18F-FDG PET. J Nucl Med 2010;51:704–12.
   PubMed Web of Science ®Google Scholar
• Brenner B, Shah MA, Gonen M, Klimstra DS, Shia J, Kelsen DP. Small-cell carcinoma of the gastrointestinal tract: A retrospective study of 64 cases. Br J Cancer 2004;90:1720–6.
   PubMed Web of Science ®Google Scholar
• Ku GY, Minsky BD, Rusch VW, Bains M, Kelsen DP, Ilson DH. Small-cell carcinoma of the esophagus and gastroesophageal junction: Review of the Memorial Sloan-Kettering experience. Ann Oncol 2008;19:533–7.
   PubMed Web of Science ®Google Scholar
• Welin S, Sorbye H, Sebjornsen S, Knappskog S, Busch C, Oberg K. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 2011;117:4617–22.
   PubMed Web of Science ®Google Scholar
• Hentic O, Hammel P, Couvelard A, Rebours V, Zappa M, Palazzo M, et al. FOLFIRI regimen: An effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. Endocr Relat Cancer 2012;19:751–7.
   PubMed Web of Science ®Google Scholar
• Strosberg JR, Coppola D, Klimstra DS, Phan AT, Kulke MH, Wiseman GA, et al. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas 2010;39:799–800.
   PubMed Web of Science ®Google Scholar